Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 18/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.51 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476158 | 0.91 | NPC1 (0.56) | — | |
| SCHEMBL30590268 | 0.90 | SMYD3 (0.63) | SMYD3PRSS1PRSS2PRSS3ST14 | |
| SCHEMBL4260732 | 0.85 | SMYD3 (0.55) | SMYD3PRSS1PRSS2PRSS3ST14 | |
| SCHEMBL4260734 | 0.85 | SMYD3 (0.55) | SMYD3PRSS1PRSS2PRSS3ST14 | |
| SCHEMBL24359879 | 0.83 | NPC1 (0.49) | — | |
| SCHEMBL24359915 | 0.83 | NPC1 (0.71) | SMYD3 | |
| SCHEMBL3809790 | 0.83 | NPC1 (0.71) | SMYD3 | |
| SCHEMBL19701286 | 0.83 | SMYD3 (0.71) | SMYD3 | |
| SCHEMBL21490142 | 0.83 | SMYD3 (0.71) | SMYD3 | |
| Hydrochloric Acid SCHEMBL25258854 | 0.82 | NPC1 (0.69) | SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818772-B2 | DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS | ABBOTT LABORATORIES | 2004-11-16 | — | — | US | disclosed |
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | ABBVIE INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003070244-A1 | ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | MCHR1, MCHR2, MC1R | SMYD3 1157/4885PRSS1 1568/4885PRSS2 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.